Neurotech International @NeurotechInt

We were pleased to have Bonni Goldstein, MD, Chief Medical Advisor (USA), present Neurotech's poster, A Novel, Pharmaceutical-grade Cannabis Extract (NTI164) in Pediatric Neurodevelopmental Disorders, at CannMed 2026. CannMed brings together leading clinicians, researchers and industry experts from around the world to advance cannabinoid science through rigorous research and collaboration.   Dr Goldstein highlighted the strong interest in NTI164 from the scientific and medical community, particularly its pharmaceutical-grade, non-intoxicating formulation and its potential to target the underlying pathophysiology of neurodevelopmental disorders, including autism spectrum disorder, Rett syndrome and PANS, rather than simply managing symptoms. $NTI

Autism spectrum disorder affects every child differently, which is why measuring treatment outcomes requires a personalised approach. In this video, Professor Michael Fahey, Paediatric Neurologist and Neurogeneticist at Monash Children's Hospital and Principal Investigator of the NTI164 clinical trials, discusses why the NTI164 clinical program was designed to recognise the diversity of autism spectrum disorder rather than expect the same response from every participant. Professor Fahey explains how the clinical trials have measured outcomes across a range of symptom domains, reflecting the individual needs and experiences of each child. He also discusses the learnings from the Phase 1 and Phase 2 studies and how they have helped shape the design of Neurotech's planned Phase 3 trial. $NTI #Autism #ASD

We've secured Notices of Allowance from the United States Patent and Trademark Office (USPTO) for two U.S. patent applications relating to key aspects of NTI164. The allowed claims cover methods of reducing neuroinflammation using NTI164 and methods of treating autism spectrum disorder (ASD). Once granted, the patents are expected to further strengthen Neurotech's intellectual property portfolio for NTI164, with intellectual property protection expected through to 2042. As we enter the new financial year, we remain focused on achieving key milestones for NTI164 to address the urgent need for effective treatments for children diagnosed with ASD. Read the full $NTI ASX Announcement here: api.investi.com.au/api/announceme… #Autism #AutismSpectrumDisorder #ASX #Biotech

For many families, the search for a new treatment begins when every other option has been exhausted. In this video, Jeanette Costac shares her family's experience before her son Sebastian participated in Neurotech's Harmony Study. Jeanette reflects on the challenges Sebastian faced, including self-harming behaviours, aggression and an inability to communicate what he was feeling. She also speaks candidly about the emotional toll this had on her as a parent and how it ultimately led her to seek treatment for her own anxiety and depression. When the opportunity arose for Sebastian to participate in the NTI164 clinical trial, Jeanette says the decision was an easy one because she was determined to find another option for her son. Jeanette's story highlights the urgent need for new treatment options for children living with neurodevelopmental conditions and reinforces Neurotech's commitment to advancing NTI164. $NTI

One of the questions often asked by families is whether the benefits observed with NTI164 can be sustained over time. In this video, Libby Harper, mother of former Harmony Study participant Tate, responds to an audience question about long-term outcomes, including whether there have been setbacks, regressions or the need to increase treatment as children grow. Libby shares her experience of Tate's journey, describing a steady pattern of continued progress over time. She also reflects on a one to two week interruption in NTI164 supply during the trial, when some of Tate's overwhelm gradually returned. For Libby, that period reinforced just how far Tate had come and the difference she felt NTI164 was making in his daily life. Watch Libby's story below. $NTI #Neurotech #ASD #Biotech #Autism

For many families living with autism spectrum disorder, finding effective treatment options can be a long and challenging journey. In this video, Libby Harper, mother of former Harmony Study participant Tate, shares her family's experience before and after Tate's participation in Neurotech's NTI164 clinical trial. Before the trial, Tate was frequently overwhelmed, struggled to remain at school and experienced significant challenge. Despite years of support, including speech therapy, occupational therapy, psychology, social groups and multiple medications, Libby felt they had exhausted all available options. Libby then reflects on the changes she observed following treatment with NTI164, including Tate attending school full-time, developing friendships, discontinuing other medications and participating more confidently in everyday life. Her story highlights the meaningful impact that improvements in core symptoms can have on both patients and their families, and why Neurotech remains focused on advancing NTI164 for children living with neurodevelopmental conditions. Watch Libby's story below. $NTI

The development of NTI164 has always been guided by a commitment to rigorous science and clinical evidence. In this video, Professor Michael Fahey, Paediatric Neurologist and Neurogeneticist at Monash Children's Hospital and Principal Investigator of the NTI164 clinical trials, discusses the decision to advance NTI164 through formal clinical studies.   Professor Fahey explains why it was important to generate robust, credible data on the potential benefits of NTI164 in children with autism spectrum disorder, despite the time and complexity involved in the clinical trial process.   He also reflects on the Phase 1 study, where more than 90% of participants reported a benefit, despite the trial being designed primarily to assess safety.   $NTI #Neurotech #Biotech #ASD #Autism #Rettsyndrome

"We believe that we have that therapy potentially with NTI 164." In case you missed it, Neurotech International CEO & Managing Director Dr Anthony Filippis' presentation from the Gold Coast Investment Showcase is now available. Watch the replay here: youtu.be/ugOG73oeMg4?si… $NTI #ASX #Biotech #NTI164 #Investing

Behind every clinical trial participant is a family with their own story. In this video, Jeanette Costac shares her experience as the mother of three boys on the autism spectrum, including two who participated in Neurotech's clinical trials under the care of Professor Michael Fahey.   Jeanette reflects on the challenges her family faced before Sebastian entered the trial, describing a period when seizures, aggressive behaviours and the side effects of multiple medications were having a significant impact on both Sebastian and their family. She also speaks candidly about the toll this took on her own wellbeing as a parent and carer.   Jeanette's story highlights the profound challenges faced by many families living with neurodevelopmental conditions and why Neurotech remains focused on advancing NTI164 for children and families in need of new treatment options. $NTI

Thank you to everyone who stopped by the Neurotech booth at the Gold Coast Investment Showcase and took the time to come and say hello. For those who missed Managing Director and CEO Dr Anthony Filippis ’ presentation, we will share the replay as soon as it becomes available in the coming days. Thank you again for your interest and support. $NTI

keyboard_arrow_left Previous keyboard_arrow_right Next

Thank you to everyone who attended today’s presentation by Managing Director and CEO Dr Anthony Filippis at the 2026 Gold Coast Investment Showcase. Anthony provided an update on Neurotech’s progress, including the development of NTI164 and the Company’s upcoming clinical and corporate milestones. For those who were unable to attend, we will share a replay of the presentation as soon as it becomes available. If you’re attending the conference, we invite you to stop by the Neurotech booth and meet with Anthony and the Neurotech team to learn more about the Company and our development programs. We look forward to seeing you there. $NTI

keyboard_arrow_left Previous keyboard_arrow_right Next

REMINDER | We’re looking forward to attending the Gold Coast Investment Showcase on 11 and 12 June 2026 at the JW Marriott Gold Coast Resort & Spa, Queensland. Managing Director and CEO Dr Anthony Filippis will present on Thursday, 11 June at 12:00 pm, providing an update on Neurotech’s recent progress and upcoming milestones. For conference information and registration: goldcoastinvestmentshowcase.com.au #NTI #Neurotech @VEvents_RIU #Biotech

Thank you to everyone who joined us at Neurotech’s Investor & Advocacy Day yesterday. It was a special afternoon bringing together families, medical professionals, advocates and the Neurotech team to share experiences, discuss NTI164 and hear firsthand about the impact the treatment is having on patients and their families. We’re grateful to the families who shared their stories and to everyone who took the time to be part of the day. $NTI

keyboard_arrow_left Previous keyboard_arrow_right Next

We’re looking forward to attending the Gold Coast Investment Showcase on 11 and 12 June 2026 at the JW Marriott Gold Coast Resort & Spa, Queensland. Managing Director and CEO Dr Anthony Filippis will present on Thursday, 11 June at 12:00 pm, providing an update on Neurotech’s recent progress and upcoming milestones. For conference information and registration: goldcoastinvestmentshowcase.com.au #NTI #Neurotech @VEvents_RIU #Biotech

REMINDER | We’re hosting our Neurotech Investor & Advocacy Day on 21 May 2026. Join us for a meaningful gathering of families, professionals and community advocates to hear from the team behind Neurotech, alongside medical professionals and families sharing insights into NTI164 and the impact the treatment is having on patients and their lives. The event is an opportunity to connect, learn and support the children and families who need it most. Canapés and light refreshments will be served following the presentations. To reserve your place, RSVP $NTI by 14 May 2026 to [email protected]. #Neurotech #Investors #Biotech

We’re hosting our @NeurotechInt Investor & Advocacy Day on 21 May 2026. Join us for a meaningful gathering of families, professionals and community advocates to hear from the team behind Neurotech, alongside medical professionals and families sharing insights into NTI164 and the impact the treatment is having on patients and their lives. The event is an opportunity to connect, learn and support the children and families who need it most. Canapés and light refreshments will be served following the presentations. To reserve your place, RSVP by 14 May 2026 to [email protected]. $NTI #Neurotech #Investors #Biotech

We’ll be presenting at the 1st Australian Microcap Investment Conference in Sydney on Monday, 11 May. MD and CEO Dr Anthony Filippis will present at 3:00 pm, providing an overview of Neurotech’s strategy, clinical progress and growth outlook. Fullerton Hotel, Sydney Monday, 11 May 2026 To register: microcapconferences.com/event/sydney/r… #AusMicrocap #Biotech #ASX $NTI

Watch Managing Director and CEO Dr Anthony Filippis provide a brief update from the Ignite Summit in Hong Kong, outlining Neurotech’s recent clinical and corporate milestones and the next stage of delivery. $NTI #ASX #SmallCaps #CapitalMarkets #Mining #MarketOpen #IgniteSummit #IgnitePartners